Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth
Company Streamlines Leadership Team to Align with Plan to Grow Twirla®
James Tursi, M.D. Resigns from Board of Directors
PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a girls’s healthcare firm, at the moment introduced that it has reorganized and streamlined its govt management crew to align with its business plan to advertise Twirla® (levonorgestrel and ethinyl estradiol) transdermal system development. As half of the modifications, the Company introduced the appointment of Amy Welsh to Chief Commercial Officer efficient November 1, 2022. Additionally, James P. Tursi, M.D. has knowledgeable the Company that he’ll resign from the Company’s board of administrators efficient October 7, 2022.
“Our focus in 2022 has been on growing Twirla and advancing towards generating positive cash flow,” mentioned Agile Therapeutics Chairman and Chief Executive Officer Al Altomari. “In 2022, we have significantly reduced our operating expenses by redesigning how we work to gain efficiencies and implemented a plan we believe can drive Twirla growth through our Afaxys partnership, connected TV (CTV) campaign, and growing the telemedicine channel. The changes to our leadership team we are announcing today are expected to help us consolidate the efficiency gains we have made in our operations by streamlining my executive team and maintaining our focus on executing our business plan.”
In addition to her present tasks main the Twirla advertising crew, Ms. Welsh, as Chief Commercial Officer, will assume duty for all of the Company’s business features. Ms. Welsh joined the Company in May 2020 as Vice President, Marketing. Prior to becoming a member of Agile, Ms. Welsh was a Vice President, Marketing at Antares Pharma, Inc., and held numerous roles of growing duty at AstraZeneca.
The Company has additionally appointed Geoffrey P. Gilmore to the newly created position of Chief Administrative Officer. In this position, Mr. Gilmore might be liable for all of the Company’s normal and administrative (“G&A”) features, together with company secretary, authorized, human assets, finance, investor relations and high quality assurance. This will allow the Company to consolidate and streamline its G&A features into one group. Mr. Gilmore beforehand served because the Company’s General Counsel.
The Company’s govt management crew can even embody Robert G. Conway, the Company’s Chief Corporate Planning and Supply Chain Officer, who might be liable for the Company’s manufacturing and provide chain features in addition to company planning, and Paul Korner, M.D., M.B.A, the Company’s Chief Medical Officer, who might be liable for the Company’s medical and analysis features and might be half of the Company’s business growth crew.
On October 4, 2022, Dr. Tursi knowledgeable the board of administrators that he intends to resign from the board of administrators to focus extra of his time on his position as Executive Vice President, Global Research & Development of Endo Pharmaceuticals. Mr. Tursi joined the board of administrators in 2016 and at the moment chairs the board’s Science and Technology Committee and serves as a member of the Compensation Committee. The Company doesn’t intend to fill Dr. Tursi’s seat. The board of administrators is evaluating the way it intends to fill Dr. Tursi’s committee assignments.
“James Tursi has provided important strategic insights, guidance and support throughout his long-standing tenure on Agile’s board,” acknowledged Mr. Altomari. “On behalf of the other board members and Agile’s management team, I would like to thank James for his service to the company.”
About Agile Therapeutics, Inc.
Agile Therapeutics is a girls’s healthcare firm devoted to fulfilling the unmet well being wants of at the moment’s girls. Our product and product candidates are designed to offer girls with contraceptive choices that provide freedom from taking a day by day capsule, with out committing to a longer-acting methodology. Our preliminary product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla relies on our proprietary transdermal patch know-how, known as Skinfusion®, which is designed to permit drug supply via the pores and skin. For extra info, please go to the corporate web site at www.agiletherapeutics.com. The Company could often disseminate materials, nonpublic info on the Company’s web site, Twitter account (@agilether), and LinkedIn account.
About Twirla®
Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly mixed hormonal contraceptive (CHC) patch that accommodates the lively elements levonorgestrel (LNG), a sort of progestin, and ethinyl estradiol (EE), a sort of estrogen. Twirla is indicated to be used as a technique of contraception by girls of reproductive potential with a physique mass index (BMI) < 30 kg/m2 for whom a mixed hormonal contraceptive is suitable. Healthcare suppliers (HCPs) are inspired to contemplate Twirla’s decreased efficacy in girls with a BMI ≥ 25 to <30 kg/m2 earlier than prescribing. Twirla is contraindicated in girls with a BMI ≥ 30 kg/m2. Twirla can also be contraindicated in girls over 35 years previous who smoke.
Cigarette smoking will increase the chance of severe cardiovascular occasions from CHC use. Twirla is designed to be utilized as soon as weekly for 3 weeks, adopted by every week and not using a patch.
Forward-Looking Statements
Certain info contained on this press launch consists of “forward-looking statements” inside the which means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We could in some instances use phrases reminiscent of “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or different phrases that convey uncertainty of the longer term occasions or outcomes to determine these forward-looking statements. Our forward-looking statements are based mostly on present beliefs and expectations of our administration crew that contain dangers, potential modifications in circumstances, assumptions, and uncertainties, together with statements concerning our ongoing and deliberate manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla, together with the growing demand for Twirla, our partnership with Afaxys and its capability to advertise development, our product provide settlement with Nurx and its capability to teach sufferers about Twirla, our related TV (CTV) marketing campaign and its capability to advertise development, our future plans with respect to our present debt financing from Perceptive Advisors, our capability to grow to be money move constructive, our prospects for future financing preparations, and our working bills, monetary situation, development and methods. Any or all of the forward- wanting statements could develop into fallacious or be affected by inaccurate assumptions we would make or by recognized or unknown dangers and uncertainties. These forward-looking statements are topic to dangers and uncertainties together with dangers associated to our capability to keep up regulatory approval of Twirla and the labeling beneath any approval we get hold of, the flexibility of Corium to supply business provide in portions and high quality enough to fulfill market demand for Twirla, our capability to efficiently improve the commercialization of and improve the uptake for Twirla, the dimensions and development of the markets for Twirla and our capability to serve these markets, regulatory and legislative developments within the United States and overseas nations, our capability to acquire and keep mental property safety for Twirla and our product candidates, the results of the continued COVID-19 pandemic on our commercialization efforts, scientific trials, provide chain, operations and the operations of third events we depend on for companies reminiscent of manufacturing, advertising assist and gross sales assist, in addition to on our potential buyer base, our capability to keep up compliance with the itemizing necessities of the Nasdaq Capital Market and the opposite dangers set forth in our filings with the U.S. Securities and Exchange Commission, together with our Annual Report on Form 10-Ok and our Quarterly Reports on Form 10-Q. For all these causes, precise outcomes and developments could possibly be materially totally different from these expressed in or implied by our forward-looking statements. You are cautioned to not place undue reliance on these forward-looking statements, that are made solely as of the date of this press launch. We undertake no obligation to publicly replace such forward-looking statements to mirror subsequent occasions or circumstances.
Contact:
Matt Riley
Head of Investor Relations & Corporate Communications
[email protected]
